Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quintiles Asia Strategic Planning Director Simranjit Singh On Korea’s Clinical Trial Strategy: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

The CRO exec discusses Korea’s expanding role in global clinical trials and the rising interest among MNCs for conducting trials in Korea, as evidenced by Pfizer’s Xalkori.


Related Content

Quintiles-Invested Samsung Biologics Proceeds On Schedule
Korean Government Shifts Attention To CRO Sector In Steady Drive To Build Up Biotech Infrastructure, Biosimilars
Asia Pacific Key To Speeding Up Global Drug Development, Says Quintiles VP Anand Tharmaratnam (Part 1 Of 2)
Korea Targets Biologics, Devices, Health Care Among Economic Growth Projects For Next Decade


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts